PP-NRS response defined as a ≥4-point improvement from baseline. Data from Phase 3 clinical studies (AD: ARCADIA 1 / PN: OLYMPIA 2) post hoc descriptive analysis of daily PP‑NRS improvement; consistent results seen in ARCADIA 2 and OLYMPIA 1. Significant improvement was achieved at 48 hours (ARCADIA 1: 9% with NEMLUVIO® + TCS/TCI vs 3% with placebo + TCS/TCI, P≤0.001; OLYMPIA 2: 15% vs 3% with placebo, P≤0.005).1,3

Co-Pay Assistance
Eligible patients may pay as little as $0
The Co-Pay program helps commercially insured patients reduce or eliminate out-of-pocket costs and improve affordability.
Sign up now for more information about NEMLUVIO for PN and AD
MOA=mechanism of action; PP-NRS=Peak Pruritus Numerical Rating Scale; Q4W=every 4 weeks; TCI=topical calcineurin inhibitor; TCS=topical corticosteroid.
References: 1. Galderma Laboratories, L.P.; data on file. 2. Galderma Laboratories, L.P.; data on file. Clinical Study Report RD.06.SIR.118163 [ARCADIA LTE]; October 2023. 3. NEMLUVIO (nemolizumab-ilto) injection 30 mg Prescribing Information. Dallas, TX: Galderma Laboratories, L.P. 4. Nemmer JM, Kuchner M, Datsi A, et al. Interleukin-31 signaling bridges the gap between immune cells, the nervous system and epithelial tissues. Front Med (Lausanne). 2021;8:639097. doi:10.3389/fmed.2021.639097